Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC .S. FDA approves Bydureon Pen (exenatide extended-release for injectable suspension) for once-weekly treatment of adults with type 2 diabetes


Monday, 3 Mar 2014 02:00am EST 

AstraZeneca PLC:U.S. Food and Drug Administration (FDA) has approved the Bydureon Pen (exenatide extended-release for injectable suspension) 2 mg as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.Bydureon should not be used for treatment of patients with type 1 diabetes or diabetic ketoacidosis.Bydureon is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise.Bydureon is not a substitute for insulin.Says concurrent use of Bydureon with insulin has not been studied and is not recommended.Bydureon is the first and only once-weekly medicine for adults with type 2 diabetes. 

Company Quote

4543.5
43.5 +0.97%
31 Oct 2014